Relapsed/refractory mantle cell lymphoma patients significantly benefited from CAR T-cell therapy, with durable complete responses and manageable adverse events, according to new findings from the ZUMA-2 trial.
Additions to R-CHOP in Patients with Diffuse or Aggressive Large B-Cell Lymphoma
Two studies examine whether adding additional drugs to a standard chemotherapy regimen could improve outcomes for patients with subgroups of B-cell lymphoma.
More Evidence that CAR T-Cell Therapy Works for Many Patients with Large B-Cell Lymphoma
Two new investigations show CAR T-cell therapy works for more than just model patients enrolled in clinical trials. Follow-up analysis and data show high-risk patients with comorbidities also responded to drug.
Brian Hill, MD, PhD, and Mikkael Sekeres, MD, MS, Chair State of the Science Summit
The overall program will cover important advances in the treatment of hematologic malignancies including mantle cell lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL) and more.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cancer Center Offers Chimeric Antigen Receptor T-Cell Therapy
Learn why, when and how to refer your patients for this groundbreaking therapy.
Long-Term Follow-Up of ZUMA-1 Shows Significant Clinical Benefit (Video)
Dr. Brian Hill discusses the one-year follow-up data of the ZUMA-1 trial to confirm anti-CD19 CAR T cell therapy’s stability of response.
Autologous Hematopoietic Cell Transplant Improves Survival in Mantle Cell Lymphoma
This multicenter study shows that even with the relatively favorable outcomes of non-transplanted patients with mantle cell lymphoma in the modern era, the use of consolidation autologous stem cell transplant appears to further-improve progression-free and overall survival.
FDA OKs Zarxio as First Biosimilar Drug
Like their predecessor generic drugs, biosimilars such as the just-approved postchemotherapy agent Zarxio could exert competitive pressure that lowers the cost of proprietary biological products.
Research Sheds Light on Ethnic Discrepancies in CLL
Learn more about a Cleveland Clinic study led by oncologist Dr. Brian Hill, which links ethnicity-specific genes to chronic lymphocytic leukemia.